Display options
Cite
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med. 2012;5:139-48doi: 10.2147/PGPM.S25100.
Thumar, J., Giesen, E., & Kluger, H. M. (2012). Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics and personalized medicine, 5139-48. https://doi.org/10.2147/PGPM.S25100
Thumar, Jaykumar, et al. "Drug targets and predictive biomarkers in the management of metastatic melanoma." Pharmacogenomics and personalized medicine vol. 5 (2012): 139-48. doi: https://doi.org/10.2147/PGPM.S25100
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med. 2012;5:139-48. doi: 10.2147/PGPM.S25100. Epub 2012 Sep 28. PMID: 23226069; PMCID: PMC3513235.
Copy Download .nbib Format: NLM
Share it on

Pharmgenomics Pers Med. 2012;5:139-48. doi: 10.2147/PGPM.S25100. Epub 2012 Sep 28.

Drug targets and predictive biomarkers in the management of metastatic melanoma.

Pharmacogenomics and personalized medicine

Jaykumar Thumar, Eva Giesen, Harriet M Kluger

Affiliations

  1. Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.

PMID: 23226069 PMCID: PMC3513235 DOI: 10.2147/PGPM.S25100

Abstract

Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-4 antibody) and vemurafenib (mutant B-RAF(V600E) kinase inhibitor) by the Federal Drug Administration has led to a new era in melanoma treatment, and additional promising drugs and drug combinations are currently being investigated. As the choices of treatment for melanoma have expanded, the need to identify predictive biomarkers to tailor treatment strategies to individual tumor or immune system characteristics has become necessary. Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit. In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease.

Keywords: inhibitors; mutations; tumors; vemurafenib

References

  1. J Invest Dermatol. 2010 Jan;130(1):20-7 - PubMed
  2. J Immunother. 2009 Oct;32(8):884-5 - PubMed
  3. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  4. Cancer. 2006 May 1;106(9):2005-11 - PubMed
  5. Nature. 2010 Dec 16;468(7326):968-72 - PubMed
  6. N Engl J Med. 2011 Jun 30;364(26):2517-26 - PubMed
  7. Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3 - PubMed
  8. J Immunother. 2012 Jan;35(1):66-72 - PubMed
  9. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4 - PubMed
  10. J Clin Oncol. 1999 Jul;17(7):2105-16 - PubMed
  11. Clin Cancer Res. 2012 Mar 1;18(5):1457-63 - PubMed
  12. N Engl J Med. 2012 Feb 23;366(8):707-14 - PubMed
  13. Cancer Res. 2008 Jun 15;68(12):4853-61 - PubMed
  14. Arch Pathol Lab Med. 2012 Nov;136(11):1385-91 - PubMed
  15. Oncogene. 2007 Mar 22;26(13):1954-8 - PubMed
  16. N Engl J Med. 2010 Aug 26;363(9):809-19 - PubMed
  17. Hematol Oncol Clin North Am. 2009 Jun;23(3):529-45, ix - PubMed
  18. Dermatology. 2010;220(1):77-81 - PubMed
  19. EMBO J. 1987 Nov;6(11):3341-51 - PubMed
  20. Pigment Cell Melanoma Res. 2011 Aug;24(4):666-72 - PubMed
  21. N Engl J Med. 2010 Dec 2;363(23):2191-9 - PubMed
  22. Acta Neuropathol. 2012 Feb;123(2):223-33 - PubMed
  23. J Leukoc Biol. 1995 Jul;58(1):14-22 - PubMed
  24. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  25. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  26. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10722-7 - PubMed
  27. Cancer. 2012 Aug 15;118(16):4014-23 - PubMed
  28. Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 - PubMed
  29. Oncogene. 2003 May 15;22(19):2869-81 - PubMed
  30. Nat Clin Pract Oncol. 2008 Dec;5(12):737-40 - PubMed
  31. Clin Exp Dermatol. 2011 Mar;36(2):174-7 - PubMed
  32. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  33. Nature. 2010 Dec 16;468(7326):973-7 - PubMed
  34. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  35. J Clin Oncol. 2006 Sep 10;24(26):4340-6 - PubMed
  36. Cancer Res. 2003 Feb 15;63(4):756-9 - PubMed
  37. Am J Pathol. 2000 Mar;156(3):791-5 - PubMed
  38. Nature. 2009 Jan 29;457(7229):599-602 - PubMed
  39. Diagn Mol Pathol. 2012 Mar;21(1):1-8 - PubMed
  40. Br J Cancer. 2008 Sep 2;99(5):734-40 - PubMed
  41. Nat Genet. 2003 May;34(1):108-12 - PubMed
  42. J Clin Oncol. 2011 Apr 1;29(10):1239-46 - PubMed
  43. J Clin Oncol. 2011 Jul 20;29(21):2904-9 - PubMed
  44. Pigment Cell Melanoma Res. 2011 Feb;24(1):18-20 - PubMed
  45. J Clin Oncol. 2000 Jan;18(1):158-66 - PubMed
  46. Cancer Res. 2004 Oct 1;64(19):7002-10 - PubMed
  47. Am J Surg Pathol. 2012 Dec;36(12):1796-800 - PubMed
  48. Cancer Res. 2005 Mar 15;65(6):2412-21 - PubMed
  49. Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6 - PubMed
  50. Mol Cell Biol. 2005 May;25(10):4176-88 - PubMed
  51. Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8 - PubMed
  52. Br J Cancer. 2005 Apr 25;92(8):1398-405 - PubMed
  53. Melanoma Res. 2006 Aug;16(4):267-73 - PubMed
  54. J Biol Chem. 2002 Mar 8;277(10):7920-8 - PubMed
  55. J Clin Oncol. 2008 Apr 20;26(12):2046-51 - PubMed
  56. Cancer. 2011 May 15;117(10):2202-8 - PubMed
  57. J Transl Med. 2010 Jul 14;8:67 - PubMed
  58. Mol Cancer Ther. 2009 Aug;8(8):2079-85 - PubMed
  59. JAMA. 2011 Jun 8;305(22):2327-34 - PubMed
  60. J Clin Oncol. 2009 Dec 20;27(36):6199-206 - PubMed
  61. J Clin Oncol. 2008 Nov 10;26(32):5233-9 - PubMed
  62. Clin Cancer Res. 2005 Jul 15;11(14):5153-7 - PubMed
  63. N Engl J Med. 2012 Jan 19;366(3):207-15 - PubMed
  64. N Engl J Med. 2001 Apr 5;344(14):1031-7 - PubMed
  65. Cancer Res. 2011 Aug 15;71(16):5535-45 - PubMed
  66. Pathology. 2008 Apr;40(3):295-8 - PubMed
  67. N Engl J Med. 2002 Aug 15;347(7):472-80 - PubMed
  68. Cancer J. 2011 Mar-Apr;17(2):127-33 - PubMed
  69. Cancer Res. 2002 Dec 1;62(23):6997-7000 - PubMed
  70. J Transl Med. 2011 Nov 28;9:204 - PubMed
  71. J Cutan Pathol. 2003 Oct;30(9):539-47 - PubMed
  72. Oncogene. 2010 Jan 14;29(2):227-36 - PubMed
  73. Curr Opin Immunol. 2012 Apr;24(2):207-12 - PubMed
  74. Isr Med Assoc J. 2006 Mar;8(3):164-8 - PubMed
  75. Invest New Drugs. 2012 Oct;30(5):2008-14 - PubMed

Publication Types